MARKET WIREReuters • 4h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
Why ACXP Stock Traded Steady Today — RQD Quant Desk Flash
$1.07 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.07
Acurx Pharmaceuticals Inc. (ACXP) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $5.9M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ACXP Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ACXP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, Acurx Pharmaceuticals Inc. (NASDAQ: ACXP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $1.07 (0.00% 1D, market cap $5.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ACXP ranks #686 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ACXP compare to ALZN and SKYE in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACXP carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ALZN (Alzamend Neuro Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $5.9M) and SKYE (Skye Bioscience Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M). Among the 5-stock peer group, ACXP leads on earnings multiple (N/A) while ACXP leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ACXP?
▼
Per ACXP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001736243), Acurx Pharmaceuticals Inc. generated $0 in revenue, -$8.0M in net income, and -$6.8M in free cash flow against $7.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.07 (-0.19%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-8.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ACXP)Realized 20D OHLCV Swing Band: ±10.7%
Deterministic 5-Pillar Attribution (39/100 Composite)
🔍 WHY ACXP SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (26% of score)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 26.6 (OVERSOLD (<32))
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$1.27-13.4% Next Q
47
Q2 (-2Q)Grade D$1.10+2.7% Next Q
44
Q3 (-1Q)Grade D$1.13-5.3% Next Q
42
CurrentGrade D-$1.07-7.6% Hist 90D α
39
Trajectory: D (47) → D- (39)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ACXP Turnaround Squeeze
While ACXP currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.30) and Max Pain ($1.12) forces dealer call-delta covering toward $7.92.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ACXP• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ACXP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ACXP Stock Traded Steady Today — RQD Quant Desk Flash
Acurx Pharmaceuticals Inc. (ACXP) slipped 0.00% to $1.07, trading at 2% of its 52-week range ($1.03 – $7.54). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($1.03 – $7.54) with RSI-14 at 26.6 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10.7% around $1.07 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live ACXP Headlines & Catalysts
MARKET WIREReuters • 4h ago
Oil slips more than 1% as talks continue on ending Iran war - ReutersOil slips more than 1% as talks continue on ending Iran war Reuters
MARKET WIREReuters • 5h ago
Nine people dead in Learjet crash in south Florida, officials say - ReutersNine people dead in Learjet crash in south Florida, officials say Reuters
MARKET WIREReuters • 7h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
MARKET WIRECNBC • 9h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 9h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 10h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 12h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ACXP)
- ✓Walkthrough of ACXP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ACXP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -50.46%🛡️ HOLDING TREND SUPPORT
2026-10-30O $1.09H $1.10L $1.03C $1.07VOL 63.2K
RES: $1.45SUP: $0.97SMA50: $1.30SMA200: $1.98
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ACXP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ACXP today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ACXP. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ACXP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ACXP)
Health Care Rank #686 of 1016
⚔️ ALZN vs ACXP Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ACXP vs. ALZN, SKYE, XCUR, SCNX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Acurx Pharmaceuticals Inc. (ACXP) ranks #686 by composite RQD confidence (39/100, grade D-) and #929 by equity capitalization ($5.9M). Within this direct 5-issuer industry benchmark cohort, ACXP leads on earnings valuation at N/A trailing P/E, while ACXP leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ALZN currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with ACXP at 39/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ACXP
ACTIVE
Acurx Pharmaceuticals Inc. | D- | 39/100 | — | — | -35.0% | 0.00% | $5.9M | Benchmark Subject |
| ALZN Alzamend Neuro Inc. | D | 47/100 | — | — | -35.0% | +2.52% | $5.9M | /alzn-vs-acxp → |
| SKYE Skye Bioscience Inc. | D- | 36/100 | — | — | -35.0% | -13.82% | $5.8M | /skye-vs-acxp → |
| XCUR Exicure Inc. | D- | 35/100 | — | — | -35.0% | -8.04% | $6.1M | /xcur-vs-acxp → |
| SCNX Scienture Holdings Inc. | D- | 42/100 | — | 76.8% | -35.0% | +2.65% | $5.7M | /scnx-vs-acxp → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001736243In its most recent audited fiscal period (FY2025, filed 2025-12-31), Acurx Pharmaceuticals Inc. (ACXP) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$8.0M, operating cash flow of -$6.8M, and free cash flow of -$6.8M (+34.6% YoY). On the balance sheet, ACXP closed FY2025 with $7.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$8.0M | -$6.8M | -$6.8M | $7.7M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$14.1M | -$10.4M | -$10.4M | $3.9M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$14.6M | -$9.8M | -$9.8M | — | — |
3. ACXP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ACXP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Acurx Pharmaceuticals Inc. (NASDAQ: ACXP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $1.07 (0.00% 1D, market cap $5.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ACXP ranks #686 in composite RQD confidence.
How does ACXP compare to ALZN and SKYE in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACXP carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ALZN (Alzamend Neuro Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $5.9M) and SKYE (Skye Bioscience Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M). Among the 5-stock peer group, ACXP leads on earnings multiple (N/A) while ACXP leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ACXP?
Per ACXP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001736243), Acurx Pharmaceuticals Inc. generated $0 in revenue, -$8.0M in net income, and -$6.8M in free cash flow against $7.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ACXP trading relative to its 50-day, 200-day, and 52-week technical levels?
ACXP last traded at $1.07 (0.00% on volume of 64,578 shares), positioning the stock -17.69% below its 50-day simple moving average ($1.30) and -45.96% below its 200-day simple moving average ($1.98). Across its 52-week range of $1.03 to $7.54, ACXP sits at the 0.6% percentile with a 14-day RSI of 26.6 (OVERSOLD (<32)) and an implied next-earnings move of ±10.7% ($1.00 to $1.18).
ACXP Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ACXP stock moving today?
Why ACXP Stock Traded Steady Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.